Human Craniomaxillofacial Allotransplantation

Facial Injuries Clinical Trial

Official title:

Human Craniomaxillofacial Allotransplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01889381
• Other study ID #: NA_00067257
• Status: Recruiting
• Phase: Phase 2
• Start date: August 2012
• Est. completion date: August 2031

Study information

• Verified date: August 2023
• Source: Johns Hopkins University
• Contact: Jane Littleton, CRNP, MSN
• Phone: 410-955-6875
• Email: jlittl38[@]jhmi.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from society. Although current surgical advancements can somewhat restore facial defects, this process often requires many operations and the resulting face only resembles the human face. To date, over 20 face transplants have been performed with highly encouraging functional and aesthetic results, but widespread clinical use has been limited due to the adverse effects of life-long and high-dose immunosuppression needed to prevent graft rejection. Risks include infection, cancer, and metabolic problems, all of which can greatly affect recipients' quality of life, make the procedure riskier, and jeopardize the potential benefits of face transplantation.

Study Design: This non-randomized, Phase II clinical trial will document the use of a new immunomodulatory protocol (aka - Pittsburgh Protocol, Starzl Protocol) for establishing face transplantation as a safe and effective reconstructive treatment for devastating injuries/ defects by minimizing maintenance immunosuppression therapy in face transplant patients. This protocol combines lymphocyte depletion with donor bone marrow cell infusion and has enabled graft survival using low doses of a single immunosuppressive drug followed by weaning of treatment. Initially designed for living-related solid organ donation, this regimen has been adapted for use with grafts donated by deceased donors. The investigators propose to perform 15 full or partial human face transplants employing this novel protocol.

Specific Aims: 1) To establish face transplantation as a safe and effective reconstructive strategy for the treatment of devastating facial injuries/defects; 2) To reduce the risk of rejection and enable allograft survival while minimizing the requirement for long-term, high-dose, multi-drug immunosuppression.

Significance of Research: Face transplantation could help injured individuals recover functionality, self-esteem, and the ability to reintegrate into family and social life as "whole" individuals. This protocol offers the potential for minimizing the morbidity of maintenance immunosuppression, thereby beneficially shifting the risk/benefit ratio of this life-enhancing procedure and enabling a wider clinical application of face transplantation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: August 2031
• Est. primary completion date: August 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Recent (=6 months) or remote (i.e., several decades) craniomaxillofacial injury

• Male or female and of any race, color, or ethnicity.

• Aged 18-65 years.

• Strong desire to undergo craniomaxillofacial transplantation.

• Completes the protocol informed consent form.

• Non-smoker, defined by having never smoked or having quit >6 consecutive months prior to screening.

• No co-existing medical condition which, in the opinion of the study team, could affect the immunomodulatory protocol, surgical procedure, or functional results (see Exclusion Criteria below. If the condition is amenable to treatment, the study team must agree that said condition should not significantly enhance the surgical risks of full or partial craniomaxillofacial transplantation.)

• No co-existing psycho-social problems (i.e., alcoholism, drug abuse).

• Negative for malignancy for past 5 years.

• Negative for HIV at transplant.

• Negative crossmatch with donor.

• If female of child-bearing potential, negative serum pregnancy test.

• If female of child-bearing potential, consent to use reliable contraception for at least one year following transplantation.

• Consents to cell collection, storage, and bone marrow infusion as part of the treatment regime.

• USA citizen or equivalent.

• Patient agrees to comply with the protocol and states a dedication to the immunomodulatory treatment regime.

Exclusion Criteria:

• Positive for any of the following conditions:

• Untreated sepsis.

• HIV (active or seropositive).

• Active tuberculosis.

• Active Hepatitis B infection.

• Hepatitis C.

• Viral encephalitis.

• Toxoplasmosis.

• Malignancy (within past 5 years).

• Current/recent (within 3 months of donation/screening consent) IV drug abuse.

• Paralysis of ischemic, traumatic, or congenital origin.

• Infectious, post infectious, or inflammatory (axonal or demyelinating) neuropathy.

• Toxic neuropathy (i.e. heavy metal poisoning, drug toxicity, industrial agent exposure).

• Mixed connective tissue disease.

• Conditions that, in the opinion of the study team, may impact the immunomodulatory protocol potentially exposing the recipient to an unacceptable risk under immunosuppressive treatment.

• A history of medical non-compliance.

• Sensitized recipients with high levels (50%) of panel-reactive Human Leukocyte Antigen (HLA) antibodies.

• Conditions that may impact the success of the surgical procedure or increase the risk of postoperative complications including inherited coagulopathies like Hemophilia, Von-Willebrand's disease, Protein C and S deficiency, Thrombocythemias, Thalassemias, Sickle Cell disease, etc.

• Mixed connective tissue diseases and collagen diseases can result in poor wound healing after surgery.

• Conditions that may impact functional outcomes including Lipopolysaccharidosis and amyloidosis (may impact nerve regeneration) or rare disorders of bone healing like osteopetrosis.

• Subjects with inadequate donor sites for autologous reconstruction in the event of post-transplant flap failure.

• Patients considered unsuitable per the consulted Psychiatric/ Psychologic appraisal.

Related Conditions & MeSH terms

• Congenital Abnormalities
• Craniofacial Defects
• Craniofacial Injuries
• Facial Deformity
• Facial Injuries
• Facial Transplantation
• Facies
• Traumatic Wounds and Injuries
• Wounds and Injuries

Intervention

Drug:
• Bone marrow cell-based therapy & 1-drug immunosuppression.
This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.

Locations

Country	Name	City	State
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Schneeberger S, Gorantla VS, Brandacher G, Zeevi A, Demetris AJ, Lunz JG, Metes DM, Donnenberg AD, Shores JT, Dimartini AF, Kiss JE, Imbriglia JE, Azari K, Goitz RJ, Manders EK, Nguyen VT, Cooney DS, Wachtman GS, Keith JD, Fletcher DR, Macedo C, Planinsic R, Losee JE, Shapiro R, Starzl TE, Lee WP. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg. 2013 Feb;257(2):345-51. doi: 10.1097/SLA.0b013e31826d90bb. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Graft Survival	Post-operative graft survival will be documented monthly Months 1-12 and quarterly (every 3 months) Years 2-5.	Transplantation through end of study period (up to 5 years)
Secondary	Documentation of immunosuppression required by transplanted participants to maintain graft.	Post-operative serum trough levels will be documented daily Days 1-28, semiweekly Weeks 5-12, weekly Weeks 13-25, biweekly Weeks 26-38, monthly Months 10-12, and quarterly (every 3 months) Years 2-5.	Transplantation to end of study period (up to 5 years)